Literature DB >> 3263821

Attempts to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rifampin, and bacitracin.

J S Roccaforte1, M J Bittner, C A Stumpf, L C Preheim.   

Abstract

Retrospective review of 197 patients with methicillin-resistant Staphylococcus aureus (MRSA) identified 47 in whom a regimen for eradication of MRSA colonization could be evaluated. The patients were elderly (mean age, 67.7 years), with 53% transferred from another institution and 53% treated in an intensive care unit. A mean of 47.1 days of hospitalization with an average of 4.9 antibiotics preceded the first MRSA culture. The usual regimen (mean, 6.0 days) was oral trimethoprim-sulfamethoxazole, 160/800 mg twice daily, oral rifampin, 600 mg once daily, and bacitracin ointment three times a day. Eradication succeeded in 40 patients, 9 relapsed, and MRSA persisted in 7. Twenty-four of 25 nares sites were cleared but only 16 of 22 other sites. MRSA infection eventually developed in 36%. No adverse reactions to the eradication regimen were noted. Although this treatment for MRSA carriage was safe and effective, decreased efficacy outside the nares and relapse limited its value.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263821     DOI: 10.1016/0196-6553(88)90024-7

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  8 in total

1.  Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome.

Authors:  T J Walsh; H C Standiford; A C Reboli; J F John; M E Mulligan; B S Ribner; J Z Montgomerie; M B Goetz; C G Mayhall; D Rimland
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 2.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

3.  Nasal colonization with methicillin-resistant Staphylococcus aureus: clinical implications and treatment.

Authors:  David Friedel; Michael Climo
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

4.  Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2 (IMCJ1454).

Authors:  Jun-ichiro Sekiguchi; Prasit Tharavichitkul; Tohru Miyoshi-Akiyama; Vena Chupia; Tomoko Fujino; Minako Araake; Atsushi Irie; Koji Morita; Tadatoshi Kuratsuji; Teruo Kirikae
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Combined topical and oral antimicrobial therapy for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) colonization in hospitalized patients.

Authors:  Scott K Fung; Marie Louie; Andrew E Simor
Journal:  Can J Infect Dis       Date:  2002-09

6.  Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus.

Authors:  F Parras; M C Guerrero; E Bouza; M J Blázquez; S Moreno; M C Menarguez; E Cercenado
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection.

Authors:  Susan S Huang; Daniel J Diekema; David K Warren; Gianna Zuccotti; Patricia L Winokur; Shailesh Tendolkar; Linda Boyken; Rupak Datta; Rebecca M Jones; Melissa A Ward; Tanya Aubrey; Andrew B Onderdonk; Christian Garcia; Richard Platt
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

8.  Eradication of methicillin-resistant Staphylococcus aureus with an antiseptic soap and nasal mupirocin among colonized patients--an open uncontrolled clinical trial.

Authors:  Günter Kampf; Axel Kramer
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-06-03       Impact factor: 3.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.